Full-Life Sciences Announces $63.3M Series B Financing Co-led by Prosperity7 Ventures to Advance Radiopharmaceutical Pipeline and GMP Manufacturing Capabilities

2024Year1Month4Shanghai, [Date]/Leblo/Heidelberg——Full-Life Technologies, a fully integrated international radiopharmaceutical therapy company (hereinafter referred to as“Full-Life Technologies”）, announced the completion today6330in tens of millions of U.S. dollars in financing, including4730in tens of thousands of US dollarsBSeries equity financing and1600credit line of ten thousand U.S. dollars. This financing willHelpThe company is rapidly advancing the development of its radiopharmaceutical pipeline and building its drug manufacturing capabilities, while optimizing its proprietary discovery platform.UniRDC™。With the completion of this financing round,Full-Life Technologies since2021Year8since its establishment in [Month]PlanRaised over1.1hundred million USD, including equity financing, debt financing, and government subsidies.

This $47.3 million Series B equity financing round was co-led by Prosperity7 Ventures, the diversified growth fund under Aramco Ventures, and a specialized investment fund in the life sciences sector. Participating investors included new shareholders Sky9 CAPITAL, the Xia Yan Medical USD Fund, the affiliated Flying Dart Xia Yan Fund, and Guanghua Wutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Jiachen Capital. In addition to the Series B financing, the company successfully secured a $16 million credit facility to provide flexible financial support for its pipeline development and the construction of its radiopharmaceutical production facility in Belgium.

Aysar Tayeb, Managing Director and Executive Director of Prosperity7 Ventures"Cancer remains a formidable global challenge, inflicting immense suffering and loss on patients and their families. Leveraging its exceptional design capabilities in linkers and carriers, along with its expertise in radionuclides, Full-Life Technologies is committed to addressing this challenge through the development of Radiopharmaceutical Drug Conjugates ('RDCs'). The company’s proprietary UniRDC™ platform is poised to enable broader coverage across the cancer treatment landscape. We look forward to Full-Life Technologies’ future advancements in delivering advanced and differentiated solutions that significantly improve therapeutic outcomes and quality of life for cancer patients."

Ms. Wu Yixia, Chief Financial Officer of Full-Life Technologiesstated, “This financing reflects the steadfast support of our new and existing investors for Full-Life Technologies’ strategy, as well as their confidence in the significant progress we have made in just over two years toward building a fully integrated, international radiopharmaceutical therapy company. The funds will facilitate Full-Life Technologies’ transition into a clinical-stage company and support the continued advancement of our pipeline projects and the construction of radiopharmaceutical manufacturing facilities compliant with Good Manufacturing Practice (‘GMP’) standards.”

Since completing its Series A equity financing in 2022, Full-Life Technologies has achieved multiple significant milestones, including but not limited to:

● Advance the Company’s lead drug candidate, 225Ac-FL-020, into Phase I clinical trials for the target indication of metastatic castration-resistant prostate cancer (“mCRPC”). The clinical trial is expected to be conducted simultaneously in Europe and the United States in early 2024. Full-Life Technologies’ PSMA-targeting vector FL-020 is specifically designed to deliver the high-efficiency alpha-particle emitting isotope Actinium-225.

● Built a robust preclinical portfolio featuring First-in-class and Best-in-class candidates, underpinned by the company’s proprietary, pioneering UniRDC™ discovery platform. This exclusive platform is designed to accelerate and streamline the discovery process for radiopharmaceutical conjugates.

● Acquired a 17,000-square-meter plot in the Walloon Region of Belgium and obtained the relevant building permits; construction has commenced on a modern GMP-compliant radiopharmaceutical production facility with a footprint of 4,000 square meters. This facility is designed to advance Full-Life Technologies’ end-to-end industry solutions and enable the production of a diverse portfolio of radiopharmaceuticals.

²²⁵Ac-FL-020 is an innovative next-generation PSMA radioligand therapy candidate under development by Full-Life Technologies, designed for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”). Its targeting vector, FL-020, was developed using Full-Life Technologies’ proprietary Clear-X™ linker technology, which significantly enhances drug uptake efficiency at tumor sites while ensuring rapid systemic clearance. In preclinical models, ²²⁵Ac-FL-020 has demonstrated promising antitumor efficacy.

UniRDC™ is a proprietary platform independently developed by Full-Life Technologies, designed to enhance the discovery efficiency of RDC drug candidates. The platform’s development timeline—from initial target identification to obtaining RDC candidates with human biodistribution data—does not exceed 18 months, a milestone that has been repeatedly validated. Built upon Full-Life Technologies’ robust screening capabilities, UniRDC™ encompasses a diverse range of modalities, including small molecules, cyclic peptides, and nanobodies. At its core lies a comprehensive suite of proprietary synthetic chemistry and protein engineering tools, featuring the Clear-X™ linker and Res-X™ modification technology. These toolkits have proven instrumental in rapidly converting affinity-matured binders into developmental candidates with optimal therapeutic biodistribution profiles.

Full-Life Technologies Limited (“Full-Life Technologies”) is a fully integrated, international radiopharmaceutical therapy company with offices in Belgium, Germany, and China. We are committed to building a nuclear medicine company with a complete industry chain encompassing the research and development, manufacturing, and commercialization of radiopharmaceuticals, thereby benefiting patients worldwide. We plan to address the core challenges currently impacting radiopharmaceutical R&D through innovative research focused on future therapeutic approaches. Our team comprises seasoned entrepreneurs and scientists who excel not only in managing biopharmaceutical companies but also possess deep expertise in the research and clinical development of radioisotopes.

Prosperity7 Ventures (P7) is a diversified growth fund under Aramco Ventures, the venture capital arm of Saudi Aramco, a global leader in integrated energy and chemicals. The name “Prosperity7” refers to Saudi Arabia’s first oil well—the seventh drilled in the kingdom—known as the “Well of Prosperity.” Building on this pioneering legacy, P7 takes a long-term view to invest globally, driving disruptive technological advancements and business model innovations with the aim of fostering shared prosperity and positive impact worldwide. With $1 billion in assets under management, P7 maintains investment teams in Saudi Arabia, the United States, and China. It focuses on investing in highly scalable startups in the Chinese and U.S. markets, spanning sectors such as enterprise IT, fintech, artificial intelligence, B2B, consumer technology, and health tech.